- ￥140 - 2680
- Solarbio
- 北京
- IN1830
- 2025年07月23日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 英文名：
Niflumic Acid
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
4394-00-7
- 规格：
1g/500mg/200mg/50mg/25mg/10mg/5mg/100mg
| 规格： | 1g | 产品价格： | ￥2680.0 |
|---|---|---|---|
| 规格： | 500mg | 产品价格： | ￥1700.0 |
| 规格： | 200mg | 产品价格： | ￥880.0 |
| 规格： | 50mg | 产品价格： | ￥480.0 |
| 规格： | 25mg | 产品价格： | ￥320.0 |
| 规格： | 10mg | 产品价格： | ￥210.0 |
| 规格： | 5mg | 产品价格： | ￥140.0 |
| 规格： | 100mg | 产品价格： | ￥550.0 |
| 基本信息 | |
| CAS | No.4394-00-7 |
| 中文名称 | 氟尼酸 |
| 英文名称 | Niflumic Acid |
| 别名 | Nifluril;Landruma;Forenol |
| 分子式 | C13H9F3N2O2 |
| 分子量 | 282.22 |
| 溶解性 | Soluble in DMSO ≥5mg/mL |
| 纯度 | ≥98% |
| 外观(性状) | Light yellow to yellow Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| EC | EINECS 224-516-2 |
| MDL | MFCD00010569 |
| SMILES | C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F |
| InChIKey | JZFPYUNJRRFVQU-UHFFFAOYSA-N |
| InChI | InChI=1S/C13H9F3N2O2/c14-13(15，16)8-3-1-4-9(7-8)18-11-10(12(19)20)5-2-6-17-11/h1-7H，(H，17，18)(H，19，20) |
| PubChem CID | 4488 |
| 靶点 | Chloride Channel |
| 通路 | Membrane Transporter&Ion Channel |
| 背景说明 | 是一种钙离子激活的氯离子通道阻断剂。 |
| 生物活性 | Niflumic Acid 是一种钙激活氯通道阻滞剂和 COX-2 抑制剂，其 IC50 值为 100 nM，具有抗癌活性，被用于治疗关节和肌肉疼痛。[1-5] |
| IC50 | COX-1: 100nM(IC50)[2] |
| In Vitro | Niflumic acid selectively reduces a component of noradrenaline- and 5-HT-induced pressor responses by inhibiting a mechanism which leads to the opening of voltage-gated calcium channels. Niflumic acid(10 and 30 microM)inhibited the noradrenaline and 5-HT induced increase in perfusion pressure.[1] Niflumic acid(NA)，a member of the fenamates group of NSAIDs and Cl(-)and Ca(2+)-activated Cl(-)(CAC)channels blocker，induced apoptosis(by ~8 %，24 h treatment)and potentiated(by 8-10 %)apoptotic effect of endoplasmic reticulum Ca(2+)mobilizer thapsigargin(Tg)in human erythroleukemic K562 cell line.[2] Combined niflumic acid(100 和 200 μM；48 h)-ciglitazone treatment synergistically induced apoptotic cell death，activated caspase-9，caspase-3，and induced caspase-3-mediated PARP cleavage. The combination treatment also triggered apoptosis through caspase-8/Bid/Bax activation. Combined niflumic acid-ciglitazone treatment significantly induced ER stress responses.[3] Niflumic acid has proliferation-inhibiting，invasion-suppressing，cell cycle-blocking and apoptosis-promoting effects on CNE-2Z cells through regulation of ERK/MAPK.[4] |
| 细胞实验 | Niflumic acid 30 mg/kg inhibited the secretory response of mucus granules in an asthma model.[5] |
| 数据来源文献 | [1]. Criddle DN，et al. Inhibitory action of niflumic acid on noradrenaline- and 5-hydroxytryptamine-induced pressor responses in the isolated mesenteric vascular bed of the rat. Br J Pharmacol. 1997 Mar;120(5):813-8. [2]. Kucherenko YV，et al. Niflumic acid affects store-operated Ca(2+)-permeable (SOC) and Ca (2+)-dependent K (+) and Cl (-) ion channels and induces apoptosis in K562 cells. J Membr Biol. 2014 Jul;247(7):627-38. [3]. Kim BM，et al. Combined treatment with the Cox-2 inhibitor niflumic acid and PPARγ ligand ciglitazone induces ER stress/caspase-8-mediated apoptosis in human lung cancer cells. Cancer Lett. 2011 Jan 28;300(2):134-44. [4]. Luo S，et al. Niflumic acid exhibits anti-tumor activity in nasopharyngeal carcinoma cells through affecting the expression of ERK1/2 and the activity of MMP2 and MMP9. Int J Clin Exp Pathol. 2015 Sep 1;8(9):9990-10001. [5]. Kondo M，et al. Niflumic acid inhibits goblet cell degranulation in a guinea pig asthma model. Allergol Int. 2012 Mar;61(1):133-42. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
IN1830 氟尼酸 跨膜转运/离子通道 索莱宝
￥140 - 2680
